Form 4: Castle Biosciences CFO Sells Shares

Castle Biosciences' Chief Financial Officer, Frank Stokes, sold 4,496 shares of common stock for $37.45 per share under a pre-planned trading arrangement.

Summary

• Frank Stokes, Chief Financial Officer of Castle Biosciences Inc. (CSTL), reported a sale of common stock.
• The transaction involved the disposition of 4,496 shares of common stock.
• The shares were sold at a price of $37.45 per share.
• The transaction occurred on December 11, 2025.
• Following this transaction, Frank Stokes beneficially owns 50,326 shares of Castle Biosciences common stock.
• The transaction was made pursuant to a Rule 10b5-1(c) pre-planned trading arrangement.

Sentiment

Score: 5

Explanation: The filing reports a routine insider stock sale, likely under a pre-planned 10b5-1 arrangement, which is generally neutral in sentiment. It does not provide new information on company performance or strategy.

Negatives

• An insider sale, even if pre-planned under a 10b5-1 arrangement, can sometimes be perceived negatively by some investors, potentially signaling a lack of confidence, though this is often mitigated by the pre-planned nature.

Stakeholder Impact

• Shareholders may note the insider sale, but its impact is likely minimal given the pre-planned nature of the transaction under a Rule 10b5-1(c) arrangement.

Key Dates

Keywords

Castle Biosciences, CSTL, Form 4, Insider Trading, Stock Sale, Frank Stokes, Chief Financial Officer, 10b5-1 plan